Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURI-CKD: Dotinurad vs Febuxostat in CKD Patients
jRCTs051250135Active, not recruiting
- Sponsor
- Fuji Yakuhin
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in chronic kidney disease (CKD) and hyperuricemia comparing Dotinurad group with Febuxostat group (2 arms). Primary endpoint: Change in urinary KIM-1. Started Dec 2025; status: active, not recruiting.
02
Drugs
dotinuradfebuxostat
03
Conditions
chronic kidney disease (CKD)hyperuricemia
Beyond the preview
Go deeper on jRCTs051250135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250135.